EA201890078A1 - ANTIBODY - Google Patents

ANTIBODY

Info

Publication number
EA201890078A1
EA201890078A1 EA201890078A EA201890078A EA201890078A1 EA 201890078 A1 EA201890078 A1 EA 201890078A1 EA 201890078 A EA201890078 A EA 201890078A EA 201890078 A EA201890078 A EA 201890078A EA 201890078 A1 EA201890078 A1 EA 201890078A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tnf
compounds
antibodies
bind
antibody
Prior art date
Application number
EA201890078A
Other languages
Russian (ru)
Inventor
Джеймс Филип О'Коннелл
Джон Роберт Портер
Аластер Лоусон
Даниел Джон Лайтвуд
Ребекка Джейн Вуттон
Original Assignee
Юсб Байофарма Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53784155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201890078(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юсб Байофарма Спрл filed Critical Юсб Байофарма Спрл
Publication of EA201890078A1 publication Critical patent/EA201890078A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В заявке описано, что некоторые соединения связываются с TNF и стабилизируют конформацию тримерного TNF, который связывается с рецептором TNF. Описаны также антитела, которые селективно связываются с комплексами таких соединений с членами суперсемейства TNF. Эти антитела можно использовать для определения других соединений с той же самой активностью, а также в качестве биомаркеров связывания с мишенью.The application describes that some compounds bind to TNF and stabilize the conformation of trimeric TNF, which binds to the TNF receptor. Antibodies that selectively bind to complexes of such compounds with members of the TNF superfamily are also described. These antibodies can be used to identify other compounds with the same activity, as well as biomarkers of binding to a target.

EA201890078A 2015-06-18 2015-10-22 ANTIBODY EA201890078A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1510758.4A GB201510758D0 (en) 2015-06-18 2015-06-18 Novel TNFa structure for use in therapy
PCT/EP2015/074527 WO2016202414A1 (en) 2015-06-18 2015-10-22 Antibody

Publications (1)

Publication Number Publication Date
EA201890078A1 true EA201890078A1 (en) 2018-06-29

Family

ID=53784155

Family Applications (4)

Application Number Title Priority Date Filing Date
EA201890081A EA201890081A1 (en) 2015-06-18 2015-10-22 MECHANISM OF ACTION
EA201890082A EA201890082A1 (en) 2015-06-18 2015-10-22 EPITOPE ANTIBODIES
EA201890080A EA201890080A1 (en) 2015-06-18 2015-10-22 ANALYSIS OF MODULATORS
EA201890078A EA201890078A1 (en) 2015-06-18 2015-10-22 ANTIBODY

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EA201890081A EA201890081A1 (en) 2015-06-18 2015-10-22 MECHANISM OF ACTION
EA201890082A EA201890082A1 (en) 2015-06-18 2015-10-22 EPITOPE ANTIBODIES
EA201890080A EA201890080A1 (en) 2015-06-18 2015-10-22 ANALYSIS OF MODULATORS

Country Status (16)

Country Link
US (11) US10883996B2 (en)
EP (8) EP3311171B1 (en)
JP (12) JP6781718B2 (en)
KR (2) KR102599907B1 (en)
CN (6) CN108139407B (en)
AU (2) AU2015398985A1 (en)
CA (5) CA2987827C (en)
CL (2) CL2017003189A1 (en)
EA (4) EA201890081A1 (en)
ES (5) ES2895486T3 (en)
GB (1) GB201510758D0 (en)
IL (2) IL256099B2 (en)
MX (2) MX2017015481A (en)
PL (4) PL3311171T3 (en)
PT (4) PT3311171T (en)
WO (5) WO2016202413A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016239948B2 (en) 2015-03-31 2022-03-17 Sorriso Pharmaceuticals, Inc. Polypeptides
UY36630A (en) 2015-04-17 2016-11-30 Abbvie Inc TRICYCLIC MODULATORS OF TNF SIGNALING
EP3294726A1 (en) 2015-04-17 2018-03-21 AbbVie Inc. Indazolones as modulators of tnf signaling
AR104293A1 (en) 2015-04-17 2017-07-12 Abbvie Inc INDAZOLONAS AS MODULATORS OF THE TNF SIGNALING
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
JP6928096B2 (en) * 2017-01-10 2021-09-01 イーティーエイチ・チューリッヒ Cytoprotective compounds and their use
CA3144566A1 (en) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2020254827A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288088B1 (en) 1987-04-24 1994-03-09 Teijin Limited Detection of tumor necrosis factor; monoclonal antibody and kit
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (en) 1988-09-02 1997-08-14 Dyax Corp PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING POINTS
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US4908372A (en) 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
DE3843534A1 (en) 1988-12-23 1990-07-12 Basf Ag NEW TNF POLYPEPTIDES
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
JP3672306B2 (en) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート Heterodimeric receptor library using phagemids
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
IT1249708B (en) 1991-09-23 1995-03-09 Tecnogen Scpa METHOD FOR DETERMINING THE TUMORAL NECROSIS FACTOR (TNF) IN BIOLOGICALLY ACTIVE FORM.
ATE408012T1 (en) 1991-12-02 2008-09-15 Medical Res Council PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
WO1993014083A1 (en) 1992-01-09 1993-07-22 Janssen Pharmaceutica N.V. Pharmaceutically active substituted benzimidazole derivatives
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5891679A (en) 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
CA2119089A1 (en) 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (en) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Libraries of polyclonal antibodies
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DE4440613C1 (en) 1994-11-14 1996-07-25 Leica Ag Device and method for the detection and demodulation of an intensity-modulated radiation field
TW453995B (en) 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
CN1204230A (en) 1997-12-08 1999-01-06 李建安 Protective cover for hand-held telephone set and its making method
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
EP1399435A2 (en) 2000-09-01 2004-03-24 Biogen, Inc. Pyridine derivatives useful as cd40:cd154 binding interruptors and use thereof to treat immunological complications
CA2446193C (en) 2001-06-05 2011-11-01 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused cycloalkyl urea compounds
US6632810B2 (en) 2001-06-29 2003-10-14 Kowa Co., Ltd. Cyclic diamine compound with condensed-ring groups
JP2003040888A (en) 2001-07-30 2003-02-13 Sankyo Co Ltd Imidazole derivative
MXPA05001268A (en) 2002-08-01 2005-10-06 Wyeth Corp Methods and reagents relating to inflammation and apoptosis.
ES2374068T3 (en) 2002-12-03 2012-02-13 Ucb Pharma, S.A. TEST TO IDENTIFY ANTIBODY PRODUCTION CELLS.
CA2524623A1 (en) 2003-05-09 2004-11-18 Pharmexa A/S Immunogenic human tnf alpha analogues with reduced cytotoxicity and methods of their preparation
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PT1644412E (en) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
SI1648509T1 (en) 2003-07-15 2012-12-31 Amgen Inc. Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
US7268116B2 (en) 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
TW200526780A (en) * 2004-01-06 2005-08-16 Hayashibara Biochem Lab TNF antagonists and TNF inhibitors comprising the same as the active ingredient
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
ATE537188T1 (en) 2005-05-18 2011-12-15 Ablynx Nv SERUM ALBUM BINDING PROTEINS
DE102005023617A1 (en) 2005-05-21 2006-11-23 Aspre Ag Method for mixing colors in a display
WO2007060411A1 (en) * 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
US9056905B2 (en) 2007-05-21 2015-06-16 Alderbio Holdings Llc Antibodies to TNF-α and use thereof
MX2009012493A (en) * 2007-05-21 2010-01-20 Alder Biopharmaceuticals Inc Novel rabbit antibody humanization methods and humanized rabbit antibodies.
CL2008002278A1 (en) 2007-08-03 2009-07-17 Alcon Res Ltd Method for the treatment of an eye disease related to tnfalfa; Method for attenuation of the expression of the mRNA of tace or tnfr1 in the eye of a patient.
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
US9365644B2 (en) 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
ES2861592T3 (en) 2008-06-25 2021-10-06 Novartis Ag Stable and soluble antibodies that inhibit TNF
KR20110093899A (en) 2008-11-20 2011-08-18 파나세아 바이오테크 리미티드 Tumor necrosis factor alpha inhibiting peptides and uses thereof
JP2010172307A (en) 2009-01-30 2010-08-12 Saitama Medical Univ METHOD AND APPARATUS FOR PREDICTING PHARMACOLOGICAL EFFICACY OF SOLUBLE TNFalpha/LTalpha RECEPTOR PREPARATION ON RHEUMATOID ARTHRITIS
US20120094935A1 (en) 2009-04-09 2012-04-19 West Anthony P Methods for creating or identifying compounds that bind tumor necrosis factor alpha
RU2595379C2 (en) 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. ANTIBODIES AGAINST TNF-α AND USE THEREOF
RU2012147249A (en) 2010-04-07 2014-05-20 Эббви Инк. TNF-α- BINDING PROTEINS
US8377441B2 (en) 2010-08-03 2013-02-19 National Cheng Kung University Treating breast cancer with anti-IL-19 antibody
CN110200955A (en) 2010-10-30 2019-09-06 金戴克斯治疗学有限责任公司 The iso- α acid derivative of tetrahydro, composition and method
AR084210A1 (en) 2010-12-08 2013-05-02 Abbott Lab PROTEINS OF UNION TO TNF-a
WO2012172070A1 (en) 2011-06-17 2012-12-20 Glaxo Group Limited Tumour necrosis factor receptor 1 antagonists
WO2013024040A2 (en) 2011-08-12 2013-02-21 B.S.R.C. Alexander Fleming Tnf superfamily trimerization inhibitors
BR112014030940B1 (en) * 2012-06-11 2022-09-06 UCB Biopharma SRL BENZIMIDAZOLS THAT MODULATE TNF-ALFA AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
EP2867674B1 (en) * 2012-06-28 2018-10-10 UCB Biopharma SPRL A method for identifying compounds of therapeutic interest
JP6259823B2 (en) * 2012-07-13 2018-01-10 ユーシービー バイオファルマ エスピーアールエル Imidazopyridine derivatives as modulators of TNF activity
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
EP3738605A1 (en) 2012-09-10 2020-11-18 Xencor, Inc. Methods of treating neurological diseases
KR101759687B1 (en) 2013-01-25 2017-07-19 타이몬, 엘엘씨 Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease
EP2969209A2 (en) 2013-03-12 2016-01-20 Anellotech, Inc. Regeneration of catalytic fast pyrolysis catalyst
CN105612183A (en) 2013-07-15 2016-05-25 诺和诺德股份有限公司 Antibodies that bind urokinase plasminogen activator
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JP6483697B2 (en) 2013-12-09 2019-03-13 ユーシービー バイオファルマ エスピーアールエル Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321732D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321733D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321734D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321749D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321740D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321731D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321748D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JP6469692B2 (en) 2013-12-09 2019-02-13 ユーシービー バイオファルマ エスピーアールエル Imidazopyridine derivatives as modulators of TNF activity
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
MY181019A (en) 2014-10-03 2020-12-16 Sanofi Sa Fused pentacyclic imidazole derivatives
CN107207604B (en) 2015-01-30 2021-10-26 学校法人埼玉医科大学 anti-ALK 2 antibodies
AU2016233289A1 (en) 2015-03-18 2017-11-09 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of TNF
SG11201707469WA (en) 2015-03-18 2017-10-30 Bristol Myers Squibb Co Substituted tricyclic heterocyclic compounds
ES2803650T3 (en) 2015-03-18 2021-01-28 Bristol Myers Squibb Co Heterocyclic compounds useful as TNF inhibitors
EP3294726A1 (en) 2015-04-17 2018-03-21 AbbVie Inc. Indazolones as modulators of tnf signaling
UY36630A (en) 2015-04-17 2016-11-30 Abbvie Inc TRICYCLIC MODULATORS OF TNF SIGNALING
AR104293A1 (en) 2015-04-17 2017-07-12 Abbvie Inc INDAZOLONAS AS MODULATORS OF THE TNF SIGNALING
GB201509893D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
GB201509888D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
GB201509885D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
ES2828696T3 (en) 2015-08-03 2021-05-27 Bristol Myers Squibb Co Cyclic compounds useful as modulators of TNF alpha
JP6955482B2 (en) 2015-08-03 2021-10-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Heterocyclic compounds useful as modifiers of TNF alpha
JP6968089B2 (en) 2016-04-01 2021-11-17 ユーシービー バイオファルマ エスアールエル Condensed hexacyclic imidazole derivative as a modulator of TNF activity
CN109219608B (en) 2016-04-01 2021-12-21 Ucb生物制药私人有限公司 Fused pentacyclic imidazole derivatives as modulators of TNF activity
WO2017167994A1 (en) 2016-04-01 2017-10-05 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives as modulators of tnf activity
CN109195969B (en) 2016-04-01 2021-12-21 Ucb生物制药私人有限公司 Fused pentacyclic imidazole derivatives as modulators of TNF activity
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope

Also Published As

Publication number Publication date
CL2017003246A1 (en) 2018-04-27
JP2018524311A (en) 2018-08-30
US11448655B2 (en) 2022-09-20
US11674967B2 (en) 2023-06-13
JP2021109880A (en) 2021-08-02
US20210088530A1 (en) 2021-03-25
IL256097A (en) 2018-02-28
WO2016202411A1 (en) 2016-12-22
EP3995831A1 (en) 2022-05-11
KR102599907B1 (en) 2023-11-07
JP2018522230A (en) 2018-08-09
JP2022023060A (en) 2022-02-07
EP3311171A1 (en) 2018-04-25
PT3311170T (en) 2021-11-03
IL256099B2 (en) 2024-06-01
KR20180012863A (en) 2018-02-06
CN108055865A (en) 2018-05-18
WO2016202413A1 (en) 2016-12-22
EP3311167B1 (en) 2020-09-23
JP2018524577A (en) 2018-08-30
JP2019218382A (en) 2019-12-26
US10883996B2 (en) 2021-01-05
US12055549B2 (en) 2024-08-06
CA2988516A1 (en) 2016-12-22
US20210132079A1 (en) 2021-05-06
EP3960759A1 (en) 2022-03-02
ES2895486T3 (en) 2022-02-21
JP6951256B2 (en) 2021-10-20
ES2902415T3 (en) 2022-03-28
EP3311171B1 (en) 2021-12-01
JP6752344B2 (en) 2020-09-09
JP2021153592A (en) 2021-10-07
CA2987823C (en) 2023-08-22
PL3311168T3 (en) 2023-09-18
PT3311169T (en) 2021-11-03
EP3311169A1 (en) 2018-04-25
CN111574517A (en) 2020-08-25
CN108055865B (en) 2021-06-15
PL3311170T3 (en) 2022-02-14
EA201890082A1 (en) 2018-07-31
WO2016202415A1 (en) 2016-12-22
MX2017015757A (en) 2018-04-24
US20180172701A1 (en) 2018-06-21
EA201890081A1 (en) 2018-06-29
JP6948954B2 (en) 2021-10-13
IL256099A (en) 2018-02-28
PL3311169T3 (en) 2022-01-31
CN107810419B (en) 2021-04-30
US20220074947A1 (en) 2022-03-10
ES2836769T3 (en) 2021-06-28
EP3311167A1 (en) 2018-04-25
CN111574517B (en) 2022-11-18
US20230194541A1 (en) 2023-06-22
ES2948915T3 (en) 2023-09-21
US20180171008A1 (en) 2018-06-21
CA2987827A1 (en) 2016-12-22
JP2018520668A (en) 2018-08-02
CN107810419A (en) 2018-03-16
JP6659030B2 (en) 2020-03-04
WO2016202412A1 (en) 2016-12-22
US20180231562A1 (en) 2018-08-16
WO2016202414A1 (en) 2016-12-22
EP3311170B1 (en) 2021-10-13
JP2023100010A (en) 2023-07-14
PT3311171T (en) 2022-01-20
EP3311170A1 (en) 2018-04-25
US10705094B2 (en) 2020-07-07
AU2015398984A1 (en) 2017-12-21
CN108139407A (en) 2018-06-08
PL3311171T3 (en) 2022-03-28
US20180203016A1 (en) 2018-07-19
US10775385B2 (en) 2020-09-15
PT3311168T (en) 2023-07-11
CN107771286B (en) 2021-07-30
JP7336178B2 (en) 2023-09-11
CA2988723A1 (en) 2016-12-22
CN107771286A (en) 2018-03-06
EP3311168A1 (en) 2018-04-25
US11022614B2 (en) 2021-06-01
EP3311168B1 (en) 2023-05-10
JP2021038222A (en) 2021-03-11
KR20180048571A (en) 2018-05-10
CN108290945A (en) 2018-07-17
MX2017015481A (en) 2018-02-19
US20210140972A1 (en) 2021-05-13
CA2987823A1 (en) 2016-12-22
JP2018525333A (en) 2018-09-06
AU2015398984B2 (en) 2022-05-26
EA201890080A1 (en) 2018-07-31
US10969393B2 (en) 2021-04-06
GB201510758D0 (en) 2015-08-05
IL256099B1 (en) 2024-02-01
US20200400678A1 (en) 2020-12-24
US20180172702A1 (en) 2018-06-21
CN108139407B (en) 2020-10-30
CA2987698A1 (en) 2016-12-22
JP2023052250A (en) 2023-04-11
AU2015398985A1 (en) 2017-12-21
CN108290945B (en) 2022-09-30
EP3311169B1 (en) 2021-09-29
ES2895552T3 (en) 2022-02-21
JP6781718B2 (en) 2020-11-04
CA2987827C (en) 2023-08-29
EP3988936A1 (en) 2022-04-27
CA2987698C (en) 2023-07-25
JP7159420B2 (en) 2022-10-24
CL2017003189A1 (en) 2018-07-06

Similar Documents

Publication Publication Date Title
EA201890078A1 (en) ANTIBODY
EA201792467A1 (en) HETERODIMERNYE ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
SA522431756B1 (en) Antibodies to Tigit
EA201791164A1 (en) HETERODIMERIC ANTIBODIES CONNECTING CD3 AND CD38
EA201791139A1 (en) HETERODIMERNYE ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
EA201891582A1 (en) IMMUNOSMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEYKIN-2 AND THEIR FUSED PROTEINS
EA201891983A1 (en) COMBINED THERAPY WITH ANTIBODIES TO CD73
EA201792451A1 (en) ANTIBODIES TO OX40 AND METHODS OF THEIR APPLICATION
EA201790961A1 (en) TRANSFORMATIVE CD3 / CD38 T-CELLS HETERODIMERIC IMMUNOGLOBULINS AND METHODS OF THEIR RECEIVING
EA201692504A1 (en) TRISPECIFIC BINDING MOLECULES AND METHODS OF THEIR APPLICATION
EA201791057A1 (en) ANTIGENSBELTING MOLECULES CONTAINING THERMAL LIGAND OF TNF FAMILIES
MX2017004311A (en) Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof.
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
CL2015002756A1 (en) Bispecific fc molecules
EA201690325A1 (en) BISPECIFIC MONOVALENT Fc-DIATELS, WHICH ARE CAPABLE TO BIND CD32B AND CD79b, AND THEIR APPLICATIONS
UA118029C2 (en) Human fcrn-binding modified antibodies and methods of use
EA201792193A1 (en) CONSTRUCTIONS OF BISPECIFIC ANTIBODIES FOR CDH3 AND CD3
BR112015022123A8 (en) ANTIBODIES, ANTIGEN-BINDING FRAGMENTS THEREOF WHICH SPECIFICALLY BINDING HEPCIDIN OR A HEPCIDIN PEPTIDE, USE, CONTAINER MEDIA AND KIT
EA200901119A1 (en) ANTIBODIES AGAINST ErbB3 AND THEIR APPLICATION
EA202091315A2 (en) HUMAN ANTIBODIES BINDING WITH G-PROTEIN RSV
EA201691321A1 (en) ANTIBODIES AND METHODS OF THEIR APPLICATION
EA201892440A1 (en) ANTIBODIES TO TL1A AND THEIR APPLICATIONS
EA201500502A1 (en) Binding HER3 ANTIGEN PROTEINS CONNECTING BETA HER3 BAT
EA201791691A1 (en) SINGLE-DOMAIN ANTIBODIES DIRECTED TO CD1d
EA201590918A1 (en) ANTIBODIES TO BMP-6